New England Journal of Medicine· 2019Q1
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- 1,951citations
- Q1SCImago
- 2019year
Short summary
This study establishes the cardiovascular safety of oral semaglutide in patients with type 2 diabetes.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine